Page last updated: 2024-09-04

dx 8951 and Leukocytopenia

dx 8951 has been researched along with Leukocytopenia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S	1

Trials

1 trial(s) available for dx 8951 and Leukocytopenia

Article	Year
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors	2001

Article

Year

Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12

Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors

2001